Biomarker profiles such as IDH1, EGFR, and MGMT, along with age-specific mutations in genes like TP53 and ATRX, highlight the need for customized therapies based on genetic variations and tumor behavior [23,24]. The gene discussed is MGMT; the disease is neoplasm.